Head & Neck Cancers | Clinical

A Decade of Thyroid Cancer Research Brings Precision Medicine to the Forefront of Care

February 26, 2021

The rising prevalence of thyroid cancer and thyroid nodules, especially for differentiated thyroid cancer, has brought into question the management of disease as it is known today.

Cabozantinib Lands Breakthrough Therapy Designation in RAI-Refractory Differentiated Thyroid Cancer

February 26, 2021

The FDA has granted Breakthrough Therapy Designation to cabozantinib for the potential treatment of patients with differentiated thyroid cancer that has progressed following prior therapy and who are radioactive iodine-refractory if eligible for radioactive iodine.

FDA Grants Breakthrough Therapy Designation to Tipifarnib in HRAS+ HNSCC

February 25, 2021

The FDA has granted a Breakthrough Therapy Designation to tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and neck squamous cell carcinoma with variant allele frequency ≥ 20% after disease progression on platinum-based chemotherapy.

FDA Grants Orphan Drug Designation to Apatinib in Adenoid Cystic Carcinoma

February 08, 2021

The FDA has granted Orphan Drug Designation to the small-molecule tyrosine kinase inhibitor apatinib for the treatment of the rare malignancy, adenoid cystic carcinoma.

KESTREL Study Misses Primary and Secondary End Points in Advanced HNSCC

February 05, 2021

Treatment with single-agent durvalumab did not improve overall survival when compared with the standard-of-care frontline combination of chemotherapy plus cetuximab as treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma whose tumors highly expressed PD-L1.

Second-Line Tislelizumab Demonstrates OS Benefit in Advanced Esophageal Squamous Cell Carcinoma

January 28, 2021

Tislelizumab improved overall survival compared with investigator’s choice of chemotherapy in patients with advanced unresectable or metastatic esophageal squamous cell carcinoma who have received prior systemic therapy.

Dusquetide Improves Severe Oral Mucositis, But Misses Statistical Significance in Head and Neck Cancers

December 23, 2020

Biological activity was observed with dusquetide as treatment of severe oral mucositis in patients with head and neck cancer receiving chemoradiation in the pivotal phase 3 DOM-INNATE study.

VEGFR Targeting with Cabozantinib Achieves PFS Benefit in RAI-Refractory DTC

December 22, 2020

Cabozantinib demonstrated significant improvement in progression-free survival in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to 2 prior vascular endothelial growth factor receptor-targeted therapies compared with placebo, meeting the primary end point of the pivotal phase 3 COSMIC-311 clinical trial.

Xevinapant Combination Induced Significant Overall Survival Improvements in LA-SCCHN

September 19, 2020

The addition og xevinapant to standard cisplatin-based concomitant fractionation chemoradiation therapy led to a reduction in the risk of mortality as treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

Novel IAP Inhibitor Shows Significant OS Benefit for High-Risk Head and Neck Cancer

August 13, 2020

Debio 1143, a potential first-in-class inhibitor of apoptosis proteins, demonstrated a statistically and clinically significant overall survival improvement when used in combination with chemoradiotherapy as treatment of patients with high-risk locally advanced squamous cell carcinoma of the head and neck, according to a press release from Debiopharm.